07:00 , Jun 17, 2013 |  BC Week In Review  |  Company News

RepliCel, Shiseido deal

RepliCel granted skincare company Shiseido exclusive rights to RCH-01 hair regeneration technology in Japan, China, South Korea, Taiwan and countries in the Association of Southeast Asian Nations (ASEAN). RepliCel will receive a ¥400 million ($3.9...
07:00 , May 21, 2012 |  BC Week In Review  |  Clinical News

Autologous dermal sheath cup cells: Phase I/II data

Interim data from the double-blind, placebo-controlled, Georgian Phase I/II TS001-2009 trial in 19 patients showed that injections of autologous DSCCs were well tolerated with no serious adverse events reported at 6 months. RepliCel said only...